Irinotecan Hydrochloride & Myelosuppression

22.8%

of users reported Myelosuppression

52.3%

also reported Hospitalization

55.4%

are women

Hospitalization

52.3%

Severe reaction

38.5%

Life-threatening condition

7.7%

Disability

1.5%

Irinotecan Hydrochloride: general information

30 - 39 years

5.9%

40 - 49 years

4.5%

50 - 59 years

22.0%

60 - 69 years

43.2%

70 - 79 years

24.4%